These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 17641440)
21. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO). Giovanella L; Ceriani L; Garancini S Q J Nucl Med; 2001 Mar; 45(1):115-9. PubMed ID: 11456370 [TBL] [Abstract][Full Text] [Related]
22. Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease. Hirooka Y; Li C; Takagi J; Gotoh M; Habu S; Yasaka-Nomura T; Ishihara R; Nakasone Y; Nakamura R; Morikawa R; Otake K; Nogimori T; Ishizuki Y Int J Clin Pharmacol Res; 2004; 24(4):111-6. PubMed ID: 15754915 [TBL] [Abstract][Full Text] [Related]
23. TRAb elevations occurred even in the third trimester; a case of a mother of a child with neonatal thyroid dysfunction, who received radioactive iodine therapy for Graves' disease. Suzuki N; Yoshihara A; Yoshimura Noh J; Kinoshita K; Ohnishi J; Saito M; Sugino K; Ito K Endocr J; 2020 Oct; 67(10):1019-1022. PubMed ID: 32522908 [TBL] [Abstract][Full Text] [Related]
24. Preoperative change of thyroid stimulating hormone receptor antibody level: possible marker for predicting recurrent hyperthyroidism in patients with Graves' disease after subtotal thyroidectomy. Sugino K; Mimura T; Ozaki O; Iwasaki H; Wada N; Matsumoto A; Ito K World J Surg; 1996 Sep; 20(7):801-6; discussion 806-7. PubMed ID: 8678954 [TBL] [Abstract][Full Text] [Related]
25. Measurement of anti-TSH receptor antibodies: what is the correct cut-off value? Smit MA; van Kinschot CMJ; van der Linden J; van Noord C; Kos S Neth J Med; 2020 Mar; 78(2):55-63. PubMed ID: 32332174 [TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of an automated TSI bridge immunoassay in the diagnosis of Graves' disease and its relationship to the degree of hyperthyroidism. Liu T; Zhang X; Long L; Zhou L; Chen J; Li M; Gao Y; Zhou X; Han X; Ji L BMC Endocr Disord; 2022 Aug; 22(1):218. PubMed ID: 36045442 [TBL] [Abstract][Full Text] [Related]
28. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease. Izumi Y; Takeoka K; Amino N Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219 [TBL] [Abstract][Full Text] [Related]
29. High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months. Hwang S; Shin DY; Song MK; Lee EJ Endocrine; 2015 Feb; 48(1):89-95. PubMed ID: 24968734 [TBL] [Abstract][Full Text] [Related]
30. A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy. Kung AW; Jones BM J Clin Endocrinol Metab; 1998 Feb; 83(2):514-8. PubMed ID: 9467567 [TBL] [Abstract][Full Text] [Related]
31. Affinity purification and diagnostic use of TSH receptor autoantibodies from human serum. Morgenthaler NG; Minich WB; Willnich M; Bogusch T; Hollidt JM; Weglöhner W; Lenzner C; Bergmann A Mol Cell Endocrinol; 2003 Dec; 212(1-2):73-9. PubMed ID: 14654252 [TBL] [Abstract][Full Text] [Related]
32. Performance of a third-generation TSH-receptor antibody in a UK clinic. Theodoraki A; Jones G; Parker J; Woolman E; Martin N; Perera S; Thomas M; Bunn C; Khoo B; Bouloux PM; Vanderpump MP Clin Endocrinol (Oxf); 2011 Jul; 75(1):127-33. PubMed ID: 21521291 [TBL] [Abstract][Full Text] [Related]
33. Continuously increasing sensitivity over three generations of TSH receptor autoantibody assays. Zöphel K; Roggenbuck D; Wunderlich G; Schott M Horm Metab Res; 2010 Nov; 42(12):900-2. PubMed ID: 20925015 [TBL] [Abstract][Full Text] [Related]
34. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease. Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425 [TBL] [Abstract][Full Text] [Related]
35. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay. Massart C; Gibassier J; d'Herbomez M Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193 [TBL] [Abstract][Full Text] [Related]
36. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855 [TBL] [Abstract][Full Text] [Related]
37. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs. Okamoto Y; Tanigawa S; Ishikawa K; Hamada N Endocr J; 2006 Aug; 53(4):467-72. PubMed ID: 16820704 [TBL] [Abstract][Full Text] [Related]
39. TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Tozzoli R; Bagnasco M; Giavarina D; Bizzaro N Autoimmun Rev; 2012 Dec; 12(2):107-13. PubMed ID: 22776786 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves' disease. Tozzoli R; D'Aurizio F; Villalta D; Giovanella L Clin Chem Lab Med; 2017 Jan; 55(1):58-64. PubMed ID: 27331310 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]